PeptiDream Inc
TSE:4587

Watchlist Manager
PeptiDream Inc Logo
PeptiDream Inc
TSE:4587
Watchlist
Price: 2 551 JPY -0.74% Market Closed
Market Cap: 331.7B JPY
Have any thoughts about
PeptiDream Inc?
Write Note

PeptiDream Inc
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

PeptiDream Inc
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
PeptiDream Inc
TSE:4587
Total Liabilities & Equity
ÂĄ93.4B
CAGR 3-Years
50%
CAGR 5-Years
38%
CAGR 10-Years
32%
GNI Group Ltd
TSE:2160
Total Liabilities & Equity
ÂĄ62.7B
CAGR 3-Years
28%
CAGR 5-Years
25%
CAGR 10-Years
25%
Takara Bio Inc
TSE:4974
Total Liabilities & Equity
ÂĄ125.3B
CAGR 3-Years
6%
CAGR 5-Years
12%
CAGR 10-Years
7%
Pharma Foods International Co Ltd
TSE:2929
Total Liabilities & Equity
ÂĄ33B
CAGR 3-Years
3%
CAGR 5-Years
30%
CAGR 10-Years
24%
S
StemRIM Inc
TSE:4599
Total Liabilities & Equity
ÂĄ9.1B
CAGR 3-Years
-6%
CAGR 5-Years
28%
CAGR 10-Years
N/A
C
Cuorips Inc
TSE:4894
Total Liabilities & Equity
ÂĄ6.2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

PeptiDream Inc
Glance View

Market Cap
330.6B JPY
Industry
Biotechnology

PeptiDream Inc., a biopharmaceutical powerhouse based in Japan, has carved out a formidable niche by leveraging its proprietary Peptide Discovery Platform System (PDPS) to revolutionize drug development. Founded in 2006 by a team of visionary scientists, the company has positioned itself at the cutting edge of peptide therapeutics. By using the PDPS, PeptiDream identifies and optimizes macrocyclic peptide candidates that have the potential to address a myriad of complex diseases with unmet medical needs. This platform enables the company to create highly specific peptide-based drugs that can modulate challenging targets previously deemed “undruggable” by conventional methods. For PeptiDream, innovation isn’t just a mission statement but an operational ethos that drives its strategic collaborations and partnerships across the pharmaceutical landscape. Revenue generation at PeptiDream is predominantly through multi-faceted strategic collaborations with leading global pharmaceutical companies. By partnering with industry titans, PeptiDream licenses access to its cutting-edge PDPS technology and collaborates on drug discovery and development projects. This collaborative approach allows the company to secure upfront payments, research funding, milestone payments, and potential royalties on the eventual sales of successfully commercialized drugs. By securing a steady stream of income through these partnerships, PeptiDream not only sustains its robust research and development initiatives but also fuels an innovation pipeline that positions it as a leader in the burgeoning field of peptide-based therapeutics.

Intrinsic Value
2 516.1 JPY
Overvaluation 1%
Intrinsic Value
Price

See Also

What is PeptiDream Inc's Total Liabilities & Equity?
Total Liabilities & Equity
93.4B JPY

Based on the financial report for Sep 30, 2024, PeptiDream Inc's Total Liabilities & Equity amounts to 93.4B JPY.

What is PeptiDream Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
32%

Over the last year, the Total Liabilities & Equity growth was 41%. The average annual Total Liabilities & Equity growth rates for PeptiDream Inc have been 50% over the past three years , 38% over the past five years , and 32% over the past ten years .

Back to Top